Shenzhen Salubris Pharmaceuticals Co., Ltd. 002294

Overview

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a prominent player in the pharmaceutical industry, established in 1998, with its headquarters based in Shenzhen, China. The company is engaged in a comprehensive range of pharmaceutical activities that encompass the research, development, production, and sale of medicines targeting critical therapeutic areas including cardiovascular, anti-diabetic, antineoplastic (cancer), and orthopedic treatments. Salubris has made significant strides in addressing cardiovascular and cerebrovascular diseases, diabetic foot diseases, tumors, and infections through its diversified product portfolio. It has also demonstrated a commitment to advancing biotechnological medicines, focusing on recombinant protein and monoclonal antibody drugs. In addition to its robust domestic market presence, Salubris is actively involved in the international market through the import, licensing-in, and licensing-out of medicines, notably in European markets, thereby expanding its global footprint and facilitating worldwide access to its innovative healthcare solutions.

Products and Services

The product lineup of Shenzhen Salubris Pharmaceuticals Co., Ltd. demonstrates the company's extensive capabilities in pharmaceutical manufacturing and its commitment to improving patient health across various therapeutic areas. The following are notable products and services offered by the company:

• Cardiovascular and Cerebrovascular Products: The offering includes innovative drugs like allisartan isoproxil, benazepril hydrochloride, desloratadine, and clopidogrel bisulfate tablets. Additionally, the company produces bivalirudin and pamidronate disodium injections, illustrating its expertise in addressing a range of cardiovascular conditions.
• Diabetic Foot Disease Treatment: Salubris has developed the recombinant SeV-hFGF2/dF Injection for the effective treatment of diabetic foot disease, showcasing its commitment to tackling complications of diabetes with advanced biotechnology solutions.
• Anti-Tumor and Orthopedics Medicines: The company's portfolio includes specialized treatments designed to combat cancer and support orthopedic health, reflecting its dedication to addressing critical and life-threatening conditions.
• Anti-Infection Products: Salubris provides a comprehensive array of anti-infection products, including a wide range of injections such as cefonicid sodium, ceftazidime, ceftriaxone sodium, cefminox sodium, cefuroxime sodium, cefepime hydrochloride, and cefodizime sodium. It also offers azithromycin dispersible and levetiracetam tablets, catering to various infections requiring targeted antimicrobial therapy.
• Biotechnological Drugs: Pioneering in the field of biotechnology, Salubris manufactures recombinant protein and monoclonal antibody drugs, illustrating its forward-thinking approach in leveraging biotechnological advancements to develop next-generation therapeutic agents.
• International Market Activities: Beyond its domestic achievements, Salubris engages in the import, licensing-in, and licensing-out of medicines, particularly targeting the European markets. This strategic approach enhances its global presence and ensures the international availability of its high-quality pharmaceutical products.